Understanding the cause of sporadic Alzheimer’s disease

References

• Förstl H. Contributions of German neuroscience to the concept of Alzheimer disease. In: Whitehouse PJ, Maurer K, Ballenger JF, editors. Concepts of Alzheimer disease: biological, clinical, and cultural perspectives. The Johns Hopkins University Press; Baltimore & London, UK: 2000. p. 72-82
   Google Scholar
• Neumann MA, Cohn R. Incidence of Alzheimer’s disease in large mental hospital; relation to senile psychosis and psychosis with cerebral arteriosclerosis. AMA Arch Neurol Psychiatry 1953;69(5):615-36
   Google Scholar
• Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci 1970;11(3):205-42
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215(4537):1237-9
   PubMed Web of Science ®Google Scholar
• Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 1991;12(10):383-8
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992;256(5054):184-5
   PubMed Web of Science ®Google Scholar
• Shariati SA, De Strooper B. Redundancy and divergence in the amyloid precursor protein family. FEBS Lett 2013;587(13):2036-45
   Google Scholar
• Walsh DM, Teplow DB. Alzheimer’s disease and the amyloid beta-protein. Prog Mol Biol Transl Sci 2012;107:101-24
   PubMed Web of Science ®Google Scholar
• Castellani RJ, Smith MA. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’. J Pathol 2011;224(2):147-52
   PubMed Web of Science ®Google Scholar
• Castellani RJ, Lee HG, Siedlak SL, et al. Reexamining Alzheimer’s disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis 2009;18(2):447-52
   Google Scholar
• Hong YT, Veenith T, Dewar D, et al. Amyloid imaging with carbon 11-labeled pittsburgh compound B for traumatic brain injury. JAMA Neurol 2014;71(1):23-31
   Google Scholar
• Gustafson DR, Skoog I, Rosengren L, et al. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007;78(5):461-4
   PubMed Web of Science ®Google Scholar
• Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12(10):957-65
   PubMed Web of Science ®Google Scholar
• Buchhave P, Minthon L, Zetterberg H, et al. Cerebrospinal Fluid Levels of beta-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. Arch Gen Psychiatry 2012;69(1):98-106
   PubMed Web of Science ®Google Scholar
• Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132(Pt 5):1310-23
   PubMedGoogle Scholar
• Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain 2008;131(Pt 3):665-80
   Google Scholar
• Desikan RS, Sabuncu MR, Schmansky NJ, et al. Selective disruption of the cerebral neocortex in Alzheimer’s disease. PLoS One 2010;5(9):e12853
   Google Scholar
• Chetelat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010;67(3):317-24
   PubMed Web of Science ®Google Scholar
• Henneman WJ, Vrenken H, Barnes J, et al. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 2009;73(12):935-40
   Google Scholar
• Tosun D, Schuff N, Shaw LM, et al. Relationship between CSF biomarkers of Alzheimer’s disease and rates of regional cortical thinning in ADNI data. J Alzheimers Dis 2011;26(Suppl 3):77-90
   Google Scholar
• Chetelat G, Villemagne VL, Villain N, et al. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 2012;78(7):477-84
   Google Scholar
• Schott JM, Bartlett JW, Fox NC, Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann Neurol 2010;68(6):825-34
   Google Scholar
• Fjell AM, Walhovd KB, Fennema-Notestine C, et al. Brain atrophy in healthy aging is related to CSF levels of Abeta1-42. Cereb Cortex 2010;20(9):2069-79
   Google Scholar
• Chetelat G, Villemagne VL, Pike KE, et al. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010;133(11):3349-58
   Google Scholar
• Whitwell JL, Tosakulwong N, Weigand SD, et al. Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects? Neuroimage Clin 2013;2:249-57
   PubMed Web of Science ®Google Scholar
• Mattsson N, Andreasson U, Persson S, et al. CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimers Dement 2013;9(3):251-61
   PubMed Web of Science ®Google Scholar
• Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 2013;369(4):341-50
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370(4):322-33
   PubMed Web of Science ®Google Scholar
• Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370(4):311-21
   PubMed Web of Science ®Google Scholar
• Moulder KL, Snider BJ, Mills SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther 2013;5(5):48
   PubMed Web of Science ®Google Scholar
• Fjell AM, Walhovd KB. Neuroimaging results impose new views on Alzheimer’s disease--the role of amyloid revised. Mol Neurobiol 2012;45(1):153-72
   Google Scholar
• Raz N, Lindenberger U, Rodrigue KM, et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex 2005;15(11):1676-89
   PubMed Web of Science ®Google Scholar
• Fjell AM, Walhovd KB, Fennema-Notestine C, et al. One-year brain atrophy evident in healthy aging. J Neurosci 2009;29(48):15223-31
   PubMed Web of Science ®Google Scholar
• Fjell AM, McEvoy L, Holland D, et al. Brain changes in older adults at very low risk for Alzheimer’s disease. J Neurosci 2013;33(19):8237-42
   Google Scholar
• Fjell AM, Walhovd KB, Fennema-Notestine C, et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer’s disease. J Neurosci 2010;30(6):2088-101
   Google Scholar
• Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann Neurol 2012
   Google Scholar
• Wirth M, Villeneuve S, Haase CM, et al. Associations Between Alzheimer Disease Biomarkers, Neurodegeneration, and Cognition in Cognitively Normal Older People. JAMA Neurol 2013
   Google Scholar
• Jack CR Jr, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013;81(20):1732-40
   Google Scholar
• Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010;9(1):119-28
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 2011;121(2):171-81
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18(4):351-7
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Reply: the early pathological process in sporadic Alzheimer’s disease. Acta Neuropathol 2013;126(4):615-18
   PubMed Web of Science ®Google Scholar
• Attems J, Jellinger KA. Amyloid and tau: neither chicken nor egg but two partners in crime!. Acta Neuropathol 2013;126(4):619-21
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82(4):239-59
   PubMed Web of Science ®Google Scholar
• Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58(12):1791-800
   PubMed Web of Science ®Google Scholar
• Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67(3):446-52
   PubMed Web of Science ®Google Scholar
• Mattsson N, Insel P, Nosheny R, et al. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol Aging 2014;35(3):614-22
   Google Scholar
• Mungas D, Tractenberg R, Schneider JA, et al. A 2-process model for neuropathology of Alzheimer’s disease. Neurobiol Aging 2014;35(2):301-8
   Google Scholar
• Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med 2013;368(2):117-27
   PubMed Web of Science ®Google Scholar
• Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 2013;368(2):107-16
   PubMed Web of Science ®Google Scholar
• Pepys MB. Amyloidosis. Annu Rev Med 2006;57:223-41
   PubMed Web of Science ®Google Scholar
• Mattsson N, Insel P, Nosheny R, et al. CSF protein biomarkers predicting longitudinal reduction of CSF beta-amyloid42 in cognitively healthy elders. Transl Psychiatry 2013;3:e293
   Google Scholar
• Chavez-Gutierrez L, Bammens L, et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. Embo J 2012;31(10):2261-74
   PubMed Web of Science ®Google Scholar
• Guerreiro R, Bras J, Hardy J. SnapShot: genetics of Alzheimer’s disease. Cell 2013;155(4):968-8; e961
   Google Scholar
• Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease families. PLoS One 2012;7(2):e31039
   PubMed Web of Science ®Google Scholar
• Kauwe JS, Jacquart S, Chakraverty S, et al. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer’s disease presenilin 1 mutation. Ann Neurol 2007;61(5):446-53
   Google Scholar
• Citron M, Teplow DB, Selkoe DJ. Generation of amyloid beta protein from its precursor is sequence specific. Neuron 1995;14(3):661-70
   PubMed Web of Science ®Google Scholar
• Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 2012;488(7409):96-9
   PubMed Web of Science ®Google Scholar
• Peacock ML, Warren JT Jr, Roses AD, Fink JK. Novel polymorphism in the A4 region of the amyloid precursor protein gene in a patient without Alzheimer’s disease. Neurology 1993;43(6):1254-6
   Google Scholar
• Andreasson U, Lautner R, Schott JM, et al. CSF biomarkers for Alzheimer’s pathology and the effect size of APOE varepsilon4. Mol Psychiatry 2013
   Google Scholar
• Bales KR, Liu F, Wu S, et al. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci 2009;29(21):6771-9
   PubMed Web of Science ®Google Scholar
• Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 2011;3(89):89ra57
   PubMed Web of Science ®Google Scholar
• Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci USA 2009;106(16):6820-5
   PubMed Web of Science ®Google Scholar
• Deane R, Sagare A, Hamm K, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 2008;118(12):4002-13
   PubMed Web of Science ®Google Scholar
• Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67(1):122-31
   PubMed Web of Science ®Google Scholar
• Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013;9(2):106-18
   PubMed Web of Science ®Google Scholar
• Martinez-Gonzalez NA, Sudlow CL. Effects of apolipoprotein E genotype on outcome after ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2006;77(12):1329-35
   PubMed Web of Science ®Google Scholar
• Zhou W, Xu D, Peng X, et al. Meta-analysis of APOE4 allele and outcome after traumatic brain injury. J Neurotrauma 2008;25(4):279-90
   PubMed Web of Science ®Google Scholar
• Jagust WJ, Landau SM. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 2012;32(50):18227-33
   Google Scholar
• Knickmeyer RC, Wang J, Zhu H, et al. Common Variants in Psychiatric Risk Genes Predict Brain Structure at Birth. Cereb Cortex 2013
   Google Scholar
• Dean DC 3rd, Jerskey BA, Chen K, et al. Brain differences in infants at differential genetic risk for late-onset alzheimer disease: a Cross-sectional Imaging Study. JAMA Neurol 2014;71(1):11-22
   PubMed Web of Science ®Google Scholar
• Hixson JE, Cox LA, Borenstein S. The baboon apolipoprotein E gene: structure, expression, and linkage with the gene for apolipoprotein C-1. Genomics 1988;2(4):315-23
   Google Scholar
• Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele? Ann Hum Genet 1999;63(Pt 4):301-10
   PubMedGoogle Scholar
• Scacchi R, Corbo RM, Rickards O, et al. Apolipoprotein B and E genetic polymorphisms in the Cayapa Indians of Ecuador. Hum Biol 1997;69(3):375-82
   Google Scholar
• Fujioka H, Phelix CF, Friedland RP, et al. Apolipoprotein E4 prevents growth of malaria at the intraerythrocyte stage: implications for differences in racial susceptibility to Alzheimer’s disease. J Health Care Poor Underserved 2013;24(4 Suppl):70-8
   Google Scholar
• Zetterberg H, Palmer M, Ricksten A, et al. Influence of the apolipoprotein E epsilon4 allele on human embryonic development. Neurosci Lett 2002;324(3):189-92
   Google Scholar
• Becher JC, Bell JE, McIntosh N, Keeling JW. Distribution of apolipoprotein E alleles in a Scottish healthy newborn population. Biol Neonate 2005;88(3):164-7
   Google Scholar
• Becher JC, Keeling JW, McIntosh N, et al. The distribution of apolipoprotein E alleles in Scottish perinatal deaths. J Med Genet 2006;43(5):414-18
   Google Scholar
• Han SD, Bondi MW. Revision of the apolipoprotein E compensatory mechanism recruitment hypothesis. Alzheimers Dement 2008;4(4):251-4
   PubMed Web of Science ®Google Scholar
• Ogunniyi A, Baiyewu O, Gureje O, et al. Epidemiology of dementia in Nigeria: results from the Indianapolis-Ibadan study. Eur J Neurol 2000;7(5):485-90
   PubMed Web of Science ®Google Scholar
• Jones L, Holmans PA, Hamshere ML, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One 2010;5(11):e13950
   Google Scholar
• Armstrong A, Mattsson N, Appelqvist H, et al. Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer’s Disease. Neuromolecular Med 2013
   Google Scholar
• Daborg J, Andreasson U, Pekna M, et al. Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer’s disease. J Neural Transm 2012;119(7):789-97
   Google Scholar
• Mattsson N, Tabatabaei S, Johansson P, et al. Cerebrospinal fluid microglial markers in Alzheimer’s disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med 2011;13(2):151-9
   PubMed Web of Science ®Google Scholar
• Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet 2006;368(9533):387-403
   PubMed Web of Science ®Google Scholar
• Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43(2 Pt 1):405-13
   PubMed Web of Science ®Google Scholar
• Rodier F, Campisi J, Bhaumik D. Two faces of p53: aging and tumor suppression. Nucleic Acids Res 2007;35(22):7475-84
   PubMed Web of Science ®Google Scholar
• Koike MA, Green KN, Blurton-Jones M, Laferla FM. Oligemic hypoperfusion differentially affects tau and amyloid-{beta}. Am J Pathol 2010;177(1):300-10
   Google Scholar
• Guglielmotto M, Aragno M, Autelli R, et al. The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem 2009;108(4):1045-56
   Google Scholar
• Wang X, Xing A, Xu C, et al. Cerebrovascular hypoperfusion induces spatial memory impairment, synaptic changes, and amyloid-beta oligomerization in rats. J Alzheimers Dis 2010;21(3):813-22
   Google Scholar
• Qi JP, Wu H, Yang Y, et al. Cerebral ischemia and Alzheimer’s disease: the expression of amyloid-beta and apolipoprotein E in human hippocampus. J Alzheimers Dis 2007;12(4):335-41
   Google Scholar
• Zetterberg H, Mortberg E, Song L, et al. Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid beta Levels in Humans. PLoS One 2011;6(12):e28263
   PubMed Web of Science ®Google Scholar
• Wisniewski HM, Maslinska D. Beta-protein immunoreactivity in the human brain after cardiac arrest. Folia Neuropathol 1996;34(2):65-71
   Google Scholar
• Hooshmand B, Solomon A, Kareholt I, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease. a longitudinal study. Neurology 2010;75(16):1408-14
   PubMed Web of Science ®Google Scholar
• Li J, Wang YJ, Zhang M, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 2011;76(17):1485-91
   PubMed Web of Science ®Google Scholar
• Solomon A, Kivipelto M, Wolozin B, et al. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009;28(1):75-80
   PubMed Web of Science ®Google Scholar
• Guo X, Pantoni L, Simoni M, et al. Blood pressure components and changes in relation to white matter lesions: a 32-year prospective population study. Hypertension 2009;54(1):57-62
   Google Scholar
• Reitz C, Mayeux R. Alzheimer disease: Epidemiology, Diagnostic Criteria, Risk Factors and Biomarkers. Biochem Pharmacol 2014
   Google Scholar
• Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 2013;382(9902):1405-12
   PubMed Web of Science ®Google Scholar
• Qiu C, von Strauss E, Backman L, et al. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 2013;80(20):1888-94
   PubMed Web of Science ®Google Scholar
• Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013;80(19):1778-83
   PubMed Web of Science ®Google Scholar
• Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69(24):2197-204
   PubMed Web of Science ®Google Scholar
• James BD, Bennett DA, Boyle PA, et al. Dementia from Alzheimer disease and mixed pathologies in the oldest old. Jama 2012;307(17):1798-800
   Google Scholar
• Davidson YS, Raby S, Foulds PG, et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer’s disease, late onset Alzheimer’s disease and Down’s syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol 2011;122(6):703-13
   Google Scholar
• Toledo JB, Cairns NJ, Da X, et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun 2013;1(1):65
   Google Scholar
• Jellinger KA, Attems J. Prevalence and pathology of dementia with Lewy bodies in the oldest old: a comparison with other dementing disorders. Dement Geriatr Cogn Disord 2011;31(4):309-16
   Google Scholar
• Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993;52(6):648-54
   Google Scholar
• Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009;66(2):200-8
   PubMed Web of Science ®Google Scholar
• Olichney JM, Galasko D, Salmon DP, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer’s disease. Neurology 1998;51(2):351-7
   Google Scholar
• Iadecola C. The pathobiology of vascular dementia. Neuron 2013;80(4):844-66
   PubMed Web of Science ®Google Scholar
• Wallin A, Ohrfelt A, Bjerke M. Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease. J Neurol Sci 2012;322(1-2):192-6
   Google Scholar
• Warren JD, Fletcher PD, Golden HL. The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol 2012;8(8):451-64
   Google Scholar
• Crutch SJ, Lehmann M, Schott JM, et al. Posterior cortical atrophy. Lancet Neurol 2012;11(2):170-8
   PubMed Web of Science ®Google Scholar
• Grossman M. Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol 2010;6(2):88-97
   Google Scholar
• Teichmann M, Kas A, Boutet C, et al. Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. Brain 2013;136(Pt 11):3474-88
   PubMedGoogle Scholar
• Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011;70(2):327-40
   PubMed Web of Science ®Google Scholar
• Ridgway GR, Lehmann M, Barnes J, et al. Early-onset Alzheimer disease clinical variants. multivariate analyses of cortical thickness. Neurology 2012;79(1):80-4
   Google Scholar
• Migliaccio R, Agosta F, Rascovsky K, et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 2009;73(19):1571-8
   PubMed Web of Science ®Google Scholar
• Lehmann M, Madison CM, Ghosh PM, et al. Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer’s disease. Proc Natl Acad Sci USA 2013;110(28):11606-11
   Google Scholar
• Lehmann M, Ghosh PM, Madison C, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer’s disease. Brain 2013;136(Pt 3):844-58
   Google Scholar
• Rosenbloom MH, Alkalay A, Agarwal N, et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 2011;76(21):1789-96
   PubMed Web of Science ®Google Scholar
• Rogalski E, Johnson N, Weintraub S, Mesulam M. Increased frequency of learning disability in patients with primary progressive aphasia and their first-degree relatives. Arch Neurol 2008;65(2):244-8
   PubMedGoogle Scholar
• Mesulam MM. Primary progressive aphasia and the language network: the 2013 H. Houston Merritt Lecture. Neurology 2013;81(5):456-62
   Google Scholar
• Tang-Wai DF, Graff-Radford NR, Boeve BF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004;63(7):1168-74
   PubMed Web of Science ®Google Scholar
• Gefen T, Gasho K, Rademaker A, et al. Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. Brain 2012;135(Pt 5):1554-65
   Google Scholar
• Johnson JK, Head E, Kim R, et al. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 1999;56(10):1233-9
   PubMedGoogle Scholar
• Filippini N, Rao A, Wetten S, et al. Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer’s disease. Neuroimage 2009;44(3):724-8
   Google Scholar
• Mattsson N, Portelius E, Rolstad S. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis 2012;30(4):767-78
   Google Scholar
• Moghekar A, Li S, Lu Y, et al. CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology 2013
   Google Scholar
• Le Couteur DG, Doust J, Creasey H, Brayne C. Political drive to screen for pre-dementia: not evidence based and ignores the harms of diagnosis. BMJ 2013;347:f5125
   PubMed Web of Science ®Google Scholar